Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 364

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 364
---
acticability exception.

Policies
and Practices Related to the Grant of Certain Equity Awards

From
time to time, we award stock options to our employees, including the named executive officers. Historically, the Company we awarded new-hire
option grants on or soon after a new hire’s employment start date and periodic annual refresh employee option grants, which refresh
grants are typically approved at a meeting of the compensation committee or board. Non-employee directors receive automatic initial and
annual stock option grants, at the time of a director’s appointment or election to the board and at the time of each annual meeting
of our stockholders, respectively. For additional information on our non-employee director compensation policy see below under the heading,
“Director Compensation.”

We
do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments
with option-like features. It is the Company’s practice to not grant any awards to its named executive officers when in possession
of any material nonpublic information, and to wait until such material nonpublic information has been fully disclosed, widely disseminated
to the public and at least two full business days has passed after such material nonpublic information has been disclosed.

Code
of Business Conduct and Ethics

We
have a Code of Business Conduct and Ethics that applies to our directors, officers and employees, including our principal executive officer,
principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Business
Conduct and Ethics is publicly available on our website at http://www.indaptusrx.com. We intend to satisfy the disclosure requirement
under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics, as well as
Nasdaq’s requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website
at texhe address and location specified above. The information contained on our website is not incorporated by reference into this Annual
Report.

Insider
Trading Policy

We
have adopted an insider trading policy that governs the purchase, sale, and/or other transactions of our securities by our directors,
officers and certain other covered persons, and which is reasonably designed to promote compliance with applicable insider trading laws,
rules and regulations, and any listing standards applicable to us. A copy of our insider trading policy is filed as Exhibit 19.1 to this
Annual Report on Form 10-K. In addition